
    
      This is a Phase I, open label, multicenter, dose-escalation, safety, pharmacokinetic, and
      pharmacodynamic study of EPC2407 administered intravenously over 60 minutes on a QDx3
      schedule repeated every 21 days. Patients are enrolled and dosed at the level defined by the
      escalation scheme. The primary goal of the study design is to assess toxicity at the fixed
      dose levels according to the modified Fibonacci schema.
    
  